Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, multicenter Phase 3 trial of inebilizumab in myasthenia gravis
2020-000949-14Phase 3Active
- Sponsor
- Viela Bio
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing inebilizumab with placebo (2 arms). Primary endpoint: Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score at end of the randomized controlled period. Started Oct 2020; status: active.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-000949-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000949-14.